Battle report
Sermorelin vs Ipamorelin
A GHRH analog with older clinical literature versus a selective GH secretagogue with limited human pharmacology data.
Sermorelin's evidence base is older and more clinical in growth hormone testing contexts. Ipamorelin has human pharmacology data but lacks broad clinical outcome proof.
Sermorelin
Ipamorelin
Concise answer
Which wins: Sermorelin vs Ipamorelin?
Sermorelin's evidence base is older and more clinical in growth hormone testing contexts. Ipamorelin has human pharmacology data but lacks broad clinical outcome proof.
Battle table
Head-to-Head Comparison
| Factor | Sermorelin | Ipamorelin | Edge |
|---|---|---|---|
| Primary mechanism | GHRH analog | Growth hormone secretagogue/ghrelin-mimetic pathway | Different |
| Human evidence type | Diagnostic and selected deficiency-context literature | Human PK/PD and limited clinical exploration | Sermorelin |
| Wellness claim support | Weak for anti-aging claims | Weak for anti-aging claims | Neither |
| Clinician oversight need | High | High | Tie |
Winner map
Evidence, Safety, Legality
- Evidence: Sermorelin for older clinical diagnostic literature
- Safety: No broad winner without clinical evaluation
- Legal: Neither as a casual wellness peptide
Plain English
Takeaways
- These are hormone-axis compounds, not casual supplements.
- A biomarker response does not prove better recovery, sleep, fat loss, or longevity.
- Evaluation for growth hormone disorders should be handled by clinicians with proper testing.
Internal links
Read the Profiles
Common Questions
Which is more evidence-based?
Sermorelin has stronger older clinical context for growth hormone testing. Ipamorelin has human pharmacology data but limited outcome evidence.
Which is safer?
There is no universal safety winner. Risks depend on medical history, endocrine status, product quality, and clinical monitoring.
Can I use this comparison to choose a protocol?
No. This comparison is educational and does not provide protocols. Talk to a licensed clinician.